HOME >> MEDICINE >> NEWS
Jefferson scientists help explain statins' effects in Alzheimer's disease

Scientists at Jefferson Medical College and the Farber Institute for Neurosciences at Thomas Jefferson University in Philadelphia have taken another step in understanding the potential effects of anti-cholesterol drugs on Alzheimer's disease. They have identified a biochemical pathway that explains the activity of statins, particularly their ability to break down an early form of the protein amyloid that clusters and forms sticky plaques in the Alzheimer's brain.

The results may eventually help provide new targets for anti-amyloid drugs to help treat Alzheimer's disease. They report their findings Jan. 11, 2005 in the online journal the Public Library of Science Medicine.

Some epidemiological studies have found a link between people taking statin drugs to lower blood cholesterol and a lower incidence of Alzheimer's. Statins work by inhibiting an enzyme involved in cholesterol production, and currently is being tested in clinical trials for their possible effects in slowing the progression of Alzheimer's.

In a series of experiments, Sam Gandy, M.D., Ph.D., director of the Farber Institute for Neurosciences at Jefferson, Steve Pedrini, Ph.D., a postdoctoral fellow in Neurology in Jefferson Medical College of Thomas Jefferson University and in the Farber Institute for Neurosciences and their co-workers found evidence suggesting that an enzymatic pathway called Rho/ROCK may play an important role in the metabolism of APP (amyloid-beta peptide precursor protein), which is an early form of amyloid, and in turn, the ability of statins to break down a form of APP.

According to Dr. Gandy, APP can be broken down in two ways: "Bad cleavage" releases toxic amyloid-beta; "good cleavage" destroys it. Evidence shows that when the pathway ROCK1 is active, less good cleavage occurs. Statins, however, reduce ROCK1 activity, making it more likely that good cleavage will be in effect.

"It's particularly important to understand the pathways
'"/>


10-Jan-2005


Page: 1 2

Related medicine news :

1. Jefferson Lab medical imager spots breast cancer
2. Jefferson scientists uncover potential trigger of diabetic kidney disease
3. Uric acid may help reduce effects of spinal cord injury, Jefferson researchers find
4. Jefferson scientists find zinc may help prevent esophageal, oral cancers
5. Jefferson virologists coax HIV out of hiding
6. Jefferson scientists find way to see breast cancer activity from outside the body
7. Jefferson and Molecular Targeting Technologies, Inc. scientists create vaccine for wildlife rabies
8. Jefferson scientists use gene therapy to rescue failing hearts in animals
9. Jefferson scientists reveal how some types of rabies invade the brain
10. Jefferson neuroscientists studying new type of Alzheimers drug to halt disease progression
11. Jefferson scientists uncover new evidence to help explain statins effects in Alzheimers disease

Post Your Comments:
(Date:5/21/2013)... (PRWEB) May 21, 2013 The ... to announce four transitions for its Board of Directors. ... the Western Michigan University School of Medicine, has been ... Medical Education at the University of California San Diego, ... Executive Officer of the Nebraska Medical Center, is the ...
(Date:5/21/2013)... Lapeer, MI (PRWEB) May 21, 2013 ... Support Group meeting in Lapeer on , June 11th. ... – 8:30pm, Location: Lapeer Regional Medical Center,     Conference Room ... 48446 , These meetings are designed to assist people ... connected with one another, and to get a better ...
(Date:5/21/2013)... The birth control safety advocates at DrugRisk.com ... the contraceptive NuvaRing. A new report shows the number ... increased in recent months*. , DrugRisk was created to ... the latest safety alerts, recalls, studies and legal news. ... side effects and decide if they need legal advice. ...
(Date:5/20/2013)... 21, 2013 USA Book News announced ... to Peak Performance" won the top honor in its ... Chosen over a multitude of international titles published from ... critical acclaim from both mainstream and new age audiences ... physically and spiritually. , “The Infinity Zone” ...
(Date:5/20/2013)... The automated external defibrillator market ... categories - semi-automated and fully automated defibrillators. Based ... categories, namely, hospitals, pre-hospital, public access, alternate care, ... Automated external defibrillators play an important role in ... Considering the life-saving potential of AEDs, legislations requiring ...
Breaking Medicine News(10 mins):Health News:New Board of Directors Leadership for The Match- National Resident Matching Program® 2Health News:New Board of Directors Leadership for The Match- National Resident Matching Program® 3Health News:DrugRisk Update Shows Increase in NuvaRing Blood Clot Lawsuits 2Health News:Mystic Ink Publishing's "The Infinity Zone" Wins Top Honor - International Book Awards 2Health News:Mystic Ink Publishing's "The Infinity Zone" Wins Top Honor - International Book Awards 3Health News:North America Leads Automated External Defibrillator Market (AED), Says New Research Report at ReportsnReports.com 2Health News:North America Leads Automated External Defibrillator Market (AED), Says New Research Report at ReportsnReports.com 3
(Date:5/20/2013)... 20, 2013  Atlantic Pharmaceuticals, Inc., a specialty ... a unique technology to deter prescription drug abuse ... Anthony Soscia , has been chosen ... Chronicle ,s Health-Care Heroes Awards. The awards are ... to honor individuals and organizations demonstrating excellence and ...
(Date:5/20/2013)... 20, 2013 Enrollment of patients with Type ... dose-finding clinical trial of product candidate NewMet ™, ... for Type 2 diabetes. Elcelyx expects to complete enrollment ... June. Results of the trial,s primary endpoint of change ... and the read-out for long-term glucose lowering and weight ...
(Date:5/20/2013)... -- Neuralstem, Inc. (NYSE MKT: CUR) today reported that ... presented updated Phase I data from its spinal cord-derived ... of amyotrophic lateral sclerosis (ALS or Lou ... medical symposium in Bucharest, Romania , ... in Stem Cell Therapy," Dr. Feldman outlined the design ...
Breaking Medicine Technology:Atlantic Pharmaceuticals President Named Health Care Hero Finalist in Atlanta Business Chronicle for Drug Abuse Deterrent Technology 2Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 2Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 3Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 4Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 2Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 3Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 4
Cached News: